About Iterum Therapeutics plc - Ordinary Share (ITRM)
Iterum Therapeutics is a biopharmaceutical company focused on developing innovative antibacterial therapies to combat serious infections caused by multidrug-resistant bacteria. The company harnesses its expertise in microbiology and drug development to advance its therapeutic candidates through clinical trials, aiming to provide effective treatment options for patients with limited choices due to rising antibiotic resistance. With a commitment to addressing urgent public health challenges, Iterum Therapeutics is dedicated to delivering next-generation antibiotics that can improve patient outcomes and enhance global health. Read More
Iterum Therapeutics PLC reports Q2 2025 earnings with a wider loss than expected, but stock rises 4.15% pre-market as investors anticipate ORLYNVAH's August 2025 launch. Cash reserves extend into 2026.
After the conclusion of the US market's regular session on Monday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
The US market is yet to commence its session on Tuesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
Iterum Therapeutics' Orlynvah receives FDA approval for treating uncomplicated UTIs in adult women, marking its first approved indication and a U.S. first for oral penems.
Companies Reporting Before The Bell • Universal Stainless (NASDAQ:USAP) is expected to report quarterly earnings at $0.32 per share on revenue of $78.65 million.
